Molecular Templates, Inc. Reports Third Quarter 2023 Financial Results and Business Update Nov 13, 2023 4:11pm EST
Molecular Templates Announces First Patient Dosed in Phase 1 Trial Evaluating MT-8421, a Novel Engineered Toxin Body Targeting CTLA-4, in Advanced Solid Tumors Nov 02, 2023 4:11pm EDT
Molecular Templates Announces the Appointment of Dr. Maurizio Voi to the Role of Chief Medical Officer Sep 28, 2023 4:11pm EDT
Molecular Templates, Inc. Reports Second Quarter 2023 Financial Results and Business Update Aug 10, 2023 8:08am EDT
Molecular Templates Announces the FDA Removal of Partial Clinical Hold in the Phase 1 Clinical Trial for MT-0169 and Focuses on Extramedullary Myeloma Jun 01, 2023 7:57am EDT
